III Consensus Meeting of the Spanish Society of Liver Transplantation. Hepatitis C, living-donor liver transplantation, quality of liver grafts and of liver transplantation programs;III Reunión de consenso de la Sociedad Española de Trasplante Hepático (SETH). Hepatitis C, trasplante hepático de donante vivo, calidad de los injertos hepáticos y calidad de los programas de trasplante hepático

Cirugia Espanola

Volumn 89, Issue 8, 2011, Pages 487-504

[No Author Info available]

Author keywords

Donor; Hepatitis C virus; Liver transplantation; Living donor; Quality

Indexed keywords

ARTICLE; CONSENSUS DEVELOPMENT; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; SPAIN; STANDARD; TRANSPLANTATION; VIROLOGY;

HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; SPAIN; TISSUE AND ORGAN PROCUREMENT;

EID: 80053287561     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/j.ciresp.2011.06.005     Document Type: Article

References (94)

1. Documento de consenso de la Sociedad Española de Trasplante Hepático. Gastroenterol Hepatol 2008, 31:82-91. Sociedad Española de Trasplante Hepático.
2. Documento de consenso de la Sociedad Española de Trasplante Hepático. Acceso al trasplante hepático, indicaciones controvertidas, priorización de la lista de espera e indicadores de calidad. Cir Esp 2008, 83:290-300. Sociedad Española de Trasplante Hepático.
3. Documento de Consenso de la Sociedad Española de Trasplante Hepático: lista de espera, trasplante pediátrico e indicadores de calidad. Gastroenterol Hepatol 2009, 32:702-716. Sociedad Española de Trasplante Hepático.
4. Documento de Consenso de la Sociedad Española de Trasplante Hepático: lista de espera, trasplante pediátrico e indicadores de calidad. Cir Esp 2009, 86:331-345. Sociedad Española de Trasplante Hepático.
5. Roche B., Samuel D. Hepatitis C virus: up to the minute. Liver Transpl 2010, 16(Suppl 2):S26-S35.
6. Berenguer M., Prieto M., San Juan F., Rayón J.M., Martinez F., Carrasco D., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002, 36:202-210.
7. Gallegos-Orozco J.F., Yosephy A., Noble B., Aqel B.A., Byrne T.J., Carey E.J., et al. Natural hystory of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 2009, 15:1872-1881.
8. Berenguer M. Risk of extended criteria donors in hepatitis c virus-positive recipients. Liver Transpl 2008, 14:S45-S50.
9. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation?. J Hepatol 2005, 42:448-479.
10. Cameron A.M., Ghobrial R.M., Yersiz H., Farmer D.G., Lip- shutz G.S., Gordon S.A., et al. Optimal utilization of donor grafts with extended criteria: a single center experience in over 1000 liver transplants. Ann Surg 2006, 243:748-755.
11. Briceño J., Ciria R., Pleguezuelo M., Naranjo A., Sánchez- Hidalgo J., Ruiz-Rabelo J., et al. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007, 39:2297-2299.
12. Samuel D., Forns X., Berenguer M., Trautwein C., Burroughs A., Rizzetto M., et al. Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis. J Hepatol 2006, 45:127-143.
13. Feray C., Gigou M., Samuel D., Paradis V., Mishiro S., Maertens G., et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease alter liver transplantation. Gastroenterology 1995, 108:1088-1096.
14. Sreekumar R., González-Koch A., Maor-Kendler Y., Batts K., Moreno-Luna L., Poterucha J., et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000, 32:1125-1130.
15. Hanouneh I.A., Feldstein A.E., McCullough A.J., Miller C., Aucejo F., Yerian L., et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008, 14:1287-1293.
16. Guido M., Fagiuoli S., Tessari G., Burra P., Leandro G., Boccagni P., et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002, 50:697-700.
17. Lake J.R. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003, 9:S63-S66.
18. Berenguer M., Royuela A., Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007, 13:21-29.
19. Vivarelli M., Burra P., La Barba G., Canova D., Senzolo M., Cucchetti A., et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007, 47:793-798.
20. Sgourakis G., Radtke A., Fouzas I., Mylona S., Goumas K., Gockel I., et al. Corticosteroid-free immunosuppression in liver transplantation: ameta-analysis and meta-regression of outcomes. Transpl Int 2009, 22:892-905.
21. Segev D.L., Sozio S.M., Shin E.J., Nazarian S.M., Nathan H., Thuluvath P.J., et al. Steroid avoidance in liver transplantation:meta-analysis and meta-regression of randomized trials. Liver Transpl 2008, 14:512-525.
22. Klintmalm G.B., Washburn W.K., Rudich S.M., Heffron T.G., Teperman L.W., Fasola C., et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007, 13:1521-1531.
23. Manousou P., Samonakis D., Cholongitas E., Patch D., O'Beirne J., Dhillon A.P., et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009, 15:1783-1791.
24. Germani G., Pleguezuelo M., Villamil F., Vaghjiani S., Tsochatzis E., Andreana L., et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant 2009, 9:1725-1731.
25. Firpi R.J., Soldevila-Pico C., Morelli G.G., Cabrera R., Levy C., Clark V.C., et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010, 55:196-203.
26. Carrion J.A., Martinez-Bauer E., Crespo G., Ramirez S., Pérez-Del Pulgar S., García-Valdecasas J.C., et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009, 50:719-728.
27. Everson G.T., Trotter J., Forman L., Kugelmas M., Halprin A., Fey B., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255-262.
28. Carrion J.A., Navasa M., Garcia-Retortillo M., Garcia-Pagan J.C., Crespo G., Bruguera M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007, 132:1746-1756.
29. Berenguer M., Palau A., Aguilera V., Rayon J.M., Juan F.S., Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008, 8:679-687.
30. Chalasani N., Manzarbeitia C., Ferenci P., Vogel W., Fontana R.J., Voigt M., et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41:289-298.
31. Shergill A.K., Khalili M., Straley S., Bollinger K., Roberts J.P., Ascher N.A., et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transpl 2005, 5:118-124.
32. Wang C.S., Ko H.H., Yoshida E.M., Marra C.A., Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006, 6:1586-1599.
33. Xirouchakis E., Triantos C., Manousou P., Sigalas A., Calvaruso V., Corbani A., et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008, 15:699-709.
34. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008, 49:274-287.
35. Blasco A., Forns X., Carrión J.A., García-Pagán J.C., Gilabert R., Rimola A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006, 43:492-499.
36. Carrión J.A., Navasa M., Bosch J., Bruguera M., Gilabert R., Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006, 12:1791-1798.
37. Carrión J.A., Torres F., Crespo G., Miquel R., García-Valdecasas J.C., Navasa M., et al. Liver stiffness identifies two different patterns PF fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010, 51:23-34.
38. Carrión J.A., Navasa M., Foros X. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010, 53:962-970.
39. Marti J., Charco R., Ferrer J., Calatayud D., Rimola A., Navasa M., et al. Optimization of liver grafts in liver retransplantation: a European single- center experience. Surgery 2008, 144:762-769.
40. Ghabril M., Dickson R., Wiesner R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of hepatitis C infection. Am J Transplant 2008, 8:404-411.
41. Dubay D., Holtzman S., Adcock L., Abbey S., Greenwood S., Macleod C., et al. Adult Right-Lobe Living Liver Donors: Quality of Life. Attitudes and Predictors of Donor Outcomes. Am J Transplant 2009, 9:1169-1178.
42. De la Mata M., Cuende N., Huet J., Bernardos A., Ferrón J.A., Santoyo J., et al. Model for end.-stage liver disease score-based allocation of donors for liver transplantation: a spanish multicenter experience. Transplantation 2006, 82:1429-1435.
43. Russo M.W., LaPointe-Rudow D., Kinkhabwala MEmmond J., Brown Rs Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation. Am J Transplant 2004, 4:427-431.
44. Middleton P.F., Duffield M., Lynch S.V., Padbury R.T., House T., Stanton P., et al. Living donor liver transplantation-Adult donor outcomes: A systematic review. Liver Transpl 2006, 12:24-30.
45. Ringe B., Strong R. The dilemma of living liver donor death: to report or not to report?. Transplantation 2008, 85:790-793.
46. Marsh J.W., Gray E., Ness R., Starzl T.E. Complications of right lobe living donor liver transplantation. J Hepatol 2009, 51:715-722.
47. Melloul E., Dondero E., Paugam-Burtz C., Bouadma L., Arnulf B., Belghiti J. Living liver donor death related to complications of myeloma. Liver Transpl 2009, 15:326-329.
48. Testa G., Angelos P., Crowley-Matoka M., Siegler M. Elective surgical patients as living organ donors: a clinical and ethical innovation. Am J Transplant 2009, 9:2400-2405.
49. Valentín-Gamazo C., Malago M., Karliova M., Lutz F.J., Frilling A., Nadalin S., et al. Experience after the evaluation of 700 potential donors for living donor liver transplantation in a single center. Liver Transpl 2004, 10:1087-1096.
50. Lee S.G., Hwang S., Kim KHAhn C.S., Moon D.B., Ha T.Y., et al. Toward 300 liver transplants a year. Surg Today 2009, 39:367-373.
51. Rimola A., Llovet J., Navasa M., Bruix J., Londoño M.C., Fuster J., et al. Applicability of adult-to-adult living donor liver transplantation. J Hepatol 2005, 43:104-109.
52. Toso C., Kneteman N.M., James Shapiro A.M., Bigam D.L. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transplant Int 2009, 22:869-875.
53. Yao F.Y. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008, 8:1982-1989.
54. Duffy J.P., Vardanian A., Benjamin E. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007, 246:502-509.
55. Mazzaferro V., Chun Y., Poon R., Schwartz M.E., Yao F.Y., Mars J.W., et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008, 15:1001-1007.
56. Herrero J.I., Sangro B., Pardo F., Quiroga J., Iñarrairaegui M., Rotellar F., et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 2008, 14:272-278.
57. Bourdeaux C., Darwish A., Jamart J., Tri T.T., Janssen M., Lerut J., et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. Am J Transplant 2007, 7:440-447.
58. Diamond I.R., Fecteau A., Millis J.M., Losanoff J.E., Ng V., Song C., et al. Impact of graft type on outcome in pediatric liver transplantation: a report From Studies of Pediatric Liver Transplantation (SPLIT). Ann Surg 2007, 246:301-310.
59. Trotter J., Talamantes M., McClure M., Wachs M., Bak T., Trouillot T., et al. Right hepatic lobe donation for living donor liver transplantation: Impact on donor quality of life. Liver Transpl 2001, 7:485-493.
60. Baker T.B., Jay C.L., Ladner D.P., Preczewski L.B., Clark L., Holl B., et al. Laparoscopy-assisted and open living donor right hepatectomy: a comparative study of outcomes. Surgery 2009, 146:817-823.
61. Suh K.S., Yi N.J., Kim T., Kim J., Shin W.Y., Lee H.W., et al. Laparoscopy-assisted donor right hepatectomy using a hand port system preserving the middle hepatic vein branches. World J Surg 2009, 33:526-533.
62. Russo M., Brown R. Financial impact of adult living donation. Liver Transpl 2003, 9:S12-S15.
63. Pomfret E.A. Life insurability of the right lobe live liver donor. Liver Transpl 2005, 11:739-740.
64. Friedman A.L. Payment for living organ donation should be legalised. BMJ 2006, 333:746-748.
65. Hippen B., Matas A. Incentives for organ donation in the United States: feasible alternative or forthcoming apocalypse?. Curr Opin Organ Transplant 2009, 14:140-146.
66. Freeman R.B., Cohen J.T. Transplantation risks and the real world: what does 'high risk' really mean?. Am J Transplant 2009, 9:23-30.
67. Ghobrial R.M., Freise C.E., Trotter J.F., Tong L., Ojo A.O., Fair J.H., et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008, 135:468-476.
68. Barr M.L., Belghiti J., Villamil F.G., Pomfret E.A., Sutherland D.S., Gruessner R.W., et al. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation 2006, 81:1373-1385.
69. Real Decreto 3070/1999, de 30 de diciembre, por el que se regulan las actividades de obtneción y utilización clínica de órganos humanos y la coordinación territorial en materia de donación y trasplante de órganos y tejidos. Boletín Oficial del Estado 4 de enero de 2000, número 3: 179-90.
70. Shiffman M.L., Brown R.S., Olthoff K.M., Everson G., Miller C., Siegler M., et al. Living donor liver transplantation: summary of a conference at The National Institutes of Health. Liver Transpl 2002, 8:174-188.
71. OPTN Annual Report 2009. [consultado 5/8/2011]. Disponible en: http://optn.transplant.hrsa.gov/ar2009/.
72. ELTR Annual Report 2009. [consultado 5/8/2011]. Disponible en: http://www.eltr.org/spip.php?article181.
73. RETH Memoria Anual 2009. [consultado 5/8/2011]. Disponible en: http://www.sethepatico.org/pdf/2009/MEMORIA_RETH_2009.pdf.
74. Briceño J., Ciria R. Early Graft dysfunction after liver transplantation. Transplant Proc 2010, 42:613-623.
75. Busuttil R.W., Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003, 9:651-663.
76. Durand F., Renz J.F., Alkofer B., Burra P., Clavien P.A., Porte R.J., et al. Report of the Paris Consensus Meeting on expanded criteria donor in liver transplantation. Liver Transpl 2008, 14:1694-1707.
77. Verzaro R., Minervini M., Gridelli B. Toward " no age limit" for liver transplant donors. Transplantation 2008, 85:1819-1822.
78. McCormack L., Petrowsky H., Jochum W., Mullhaupt B., Weber M., Clavien P.-A. Use of severily steatotic grafts in liver transplantation. Ann Surg 2007, 246:940-948.
79. Cassuto J.R., Patel S.A., Tsoulfas G., Orloff M.S., Abt P.L. The cumulative effects of cold ischemic time and older donor age on liver graft survival. J Surg Res 2008, 148:38-44.
80. Reese P.P., Sonawane S.B., Thomasson A., Yeh H., Markmann J.F. Donor age and cold ischemia interact to produce inferior 90-day liver allograft survival. Transplantation 2008, 85:1737-1744.
81. Weiss S., Kotsch K., Francuski M., Reutzel-Selke A., Mantouvalou L., Klemz R., et al. Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. Am J Transplant 2007, 7:1584-1593.
82. Feng S., Goodrich N.P., Bragg-Gresham J.L., Dykstra D.M., Punch J.D., DebRoy M.A., et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006, 6:783-790.
83. Rana A., Hardy M.A., Halazun K.J., Woodland D.C., Ratner L.E., Samstein B., et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008, 8:2537-2546.
84. Halldorson J.B., Bakthavatsalam R., Fix O., Reyes J.D., Perkins J.D. D-MELD, a Simple Predictor of Post Liver Transplant Mortality for Optimization of Donor/Recipient Matching. Am J Transplant 2009, 9:318-326.
85. Ravaioli M., Grazi G.L., Cescon M., Cucchetti A., Ercolani G., Fiorentino M., et al. Liver transplantation with donors aged 60 years and above: the low liver damage strategy. Transplant Int 2009, 22:423-433.
86. Hessheimer A.J., Parramón D., Guimerà A., Erill I., Rimola A., García-Valdecasas J.C., et al. A rapid and reliable means of assessing hepatic steatosis in vivo via electrical bioimpedance. Transplantation 2009, 88:716-722.
87. Kamath P.S., Kim W.R. The model for end-stage liver disease. Hepatology 2007, 45:797-805.
88. Schaubel D.E., Sima C.S., Goodrich N.P., Feng S., Merion R.M. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008, 8:419-425.
89. Schaubel D.E., Guidinger M.K., Biggins S.W., Kalbfleisch J.D., Pomfret E.A., Sharma P., et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009, 9(part 2):970-981.
90. Briceño J., Ciria R., Pleguezuelo M., de la Mata M., Muntané J., Naranjo A., et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis c virus cirrhosis. Liver Transpl 2009, 15:37-48.
91. Fondevila C. Is extracorporeal support becoming the new standard for the preservation of DCD grafts?. Am J Transplant 2010, 10:1341-1342.
92. García-Valdecasas J.C., Fondevila C. In-vivo normothermic recirculation: an update. Curr Opin Organ Transplant 2010, 15:173-176.
93. Guía de diseño y mejora continua de procesos asistenciales. Consejería de Salud de la Junta de Andalucía. [consultado 5/8/2011]. Disponible en: http://www.juntadeandalucia.es/salud/servicios/contenidos/procesos/docs/1.pdf.
94. Fundación Europea para la Gestión de la Calidad. Introducción a la excelencia. EFQM; 2003. ISBN 90-5236-076-6.